13 results about "Furazan" patented technology

The application relates to the technical field of solar energy, in particular to a self-cleaning solar photovoltaic panel and a preparation process thereof. The application adds anhydrous ethanol, ammonia water, deionized water, methyl triethoxysilane, tetraethyl orthosilicate and octadecyl trimethoxysilane to prepare silica sol. Then, tetra(2-hydroxyethoxy)silane, polypropylene glycol, toluene diisocyanate, betulin, 3,4-diamino furazan, silica sol and a catalyst stannous octoate are added to prepare a polymer. Glass, ethylene-vinyl acetate copolymer, a cell piece and ethylene-vinyl acetate copolymer are sequentially laid in layers; the laminated assembly is assembled with a frame to obtain a solar photovoltaic panel. Finally, a coating is prepared by taking the polymer as a raw material, and the coating is coated on the solar photovoltaic panel to obtain a finished product. The finished product has good hydrophobicity and antibacterial property, and therefore has a wide application prospect.

The invention relates to the technical field of nano preparations, in particular to self-assembled nanoparticles suitable for NO synergistic phototherapy and a preparation method and application of the self-assembled nanoparticles. The invention provides a novel furazan NO donor-silicon phthalocyanine photosensitizer conjugate or a furazan NO donor-hyaluronic acid conjugate, and a preparation method of the furazan NO donor-silicon phthalocyanine photosensitizer conjugate or the furazan NO donor-hyaluronic acid conjugate. The furazan NO donor-silicon phthalocyanine photosensitizer conjugate is subjected to self-assembly preparation, or the furazan NO donor-hyaluronic acid conjugate wraps a photosensitizer or other drugs to obtain the self-assembly nanoparticles suitable for NO synergistic therapy. The nanoparticle realizes space-time co-transport of NO and the photosensitizer, has a controllable drug release behavior, and improves the tumor treatment effect. The nanoparticles can generate NO and ROS in cells, the NO and the ROS react with each other to form an active nitrogen substance, heat released by phototherapy and ROS promote release of NO, and the nanoparticles and NO cooperate to induce apoptosis of breast cancer cells or cervical cancer cells.

The invention relates to the technical field of ionic couple and electrochemical synergistic synthesis, in particular to 3, 3 '-diamino-4, 4'-azofurazan and an ionic couple and electrochemical synergistic synthesis method thereof, and the synthesis method comprises the following steps: 1, preparing CC-Co3O4: adopting nitric acid hexahydrate, ammonium fluoride, urea and carbon cloth as raw materials, and preparing the CC-Co3O4 through a hydrothermal method; 2, preparing an acidic solution of 3, 4-diaminofurazan to obtain a first solution; 3, preparing an acid solution of Ce < 4 + > to obtain a second solution; and 4, carrying out an electrocatalytic oxidation reaction by taking CC-Co3O4 as an anode, a platinum sheet as a counter electrode and the first solution as an electrolyte, dropwise adding the second solution into the electrolyte in the electrocatalytic process, and stirring, centrifuging, washing, drying and grinding after the second solution is dropwise added to obtain the 3, 3 '-diamino-4, 4'-azofurazan.

The invention discloses a compound with a benzimidazole-amino furazan-oxadiazole skeleton as well as a preparation method and application of the compound. The structure of the compound is shown in general formulas I and II. According to the present invention, butyrylcholine esterase inhibition activity, Nrf2 activation activity, in vitro pharmacodynamic experiment and Morris water maze experiment are adopted as carriers to evaluate the treatment of Alzheimer's disease (especially moderate and severe Alzheimer's disease) by using the compounds represented by the general formulas I and II, and the results show that the compounds have good in vitro and in vivo activity and extremely high selectivity; the compound can be used as a candidate lead compound for further development of an anti-Alzheimer's disease effect by selectively inhibiting butyrylcholine esterase and activating Nrf2.

The invention relates to 1: 2 metal complex red, a preparation method thereof and a dye composition, the preparation method comprises the following steps: mixing 5-sulfonic acid-7-nitrobenzofurazan, an acid-binding agent, a Lewis acid catalyst and water, adjusting the pH value to 1.9-2.1, and carrying out a ring-opening reaction, the molar ratio of 5-sulfonic acid-7-nitrobenzofurazan to the Lewis acid catalyst being 1: 0.012-0.017; pyrazolone shown in the formula (I) is added into a ring-opening reaction product, a coupling reaction is conducted under the condition that the pH ranges from 7.0 to 8.0, in the formula (I), R1 is selected from phenyl or tolyl, and R2 is selected from methyl or ethyl; a chromium solution is dropwise added into the coupling product, the molar ratio of the chromium element in the chromium solution to the coupling product is 1: (1.9-2.1), the temperature is controlled to be 75-80 DEG C in the dropwise adding process, the concentration of Cr < 3 + > is 0.02-0.03 mol / L, the temperature is increased to 95-97 DEG C after dropwise adding is completed, the pH is adjusted to 4.5-4.8, a complexation reaction is conducted, and the 1: 2 metal complex red shown in the formula (II) is obtained. The 1: 2 metal complex red with low environmental protection risk, high dyeing performance and good batch stability can be prepared.

This invention provides a method for synthesizing 3-(4-azidofurazan-3-oxomethyl)-3-azidomethyloxetane, its structural formula is shown below: The method includes the following steps: Step 1, 3-nitro-4-hydroxyfurazan, 3,3-dibromomethyloxetane, a basic donor and a phase transfer catalyst are added to a polar aprotic solvent, and the mixture is stirred at 45-85°C for 0.5-2 hours. Then, the mixture is extracted, washed with water, dried, filtered, the solvent is evaporated, and recrystallized to obtain 3-(4-azidofurazan-3-oxomethyl)-3-azidomethyloxetane. 3-(4-nitrofurazan-3-oxomethyl)-3-bromomethyloxetane; the 3-(4-nitrofurazan-3-oxomethyl)-3-bromomethyloxetane obtained in steps 2 and 1 and the azidating agent are added to a polar aprotic solvent and stirred at room temperature for 0.5-1.5 h. Then, the mixture is extracted, washed with water, dried, filtered, and the solvent is evaporated to obtain the final product. The 3-(4-azidofurazan-3-oxomethyl)-3-azidomethyloxetane prepared by this invention can be used as an energetic binder or an energetic initiator.

The present invention provides processes for preparing a compound of formula I and pharmaceutically acceptable salts thereof,comprising deprotecting a compound of formula IIwherein each R3 independently represents a tertiary alkyl group, preferably wherein each R3 is tertiary butyl. The invention also provides intermediates useful for preparing compounds of formula I and processes for preparing these intermediates. Additionally the invention provides polymorphic forms of the dichloride salt of the compound of formula I and their use in the treatment of proliferative disorders.

The invention discloses a benzofurazan derivative as well as a preparation method and application thereof, and belongs to the technical field of medicines. The structure of the benzofurazan derivative is shown in the specification. The compound has the beneficial effects that IC50 values of proliferation inhibition effects of part of compounds (compounds A3, A4, A11, A12, A13, A14, A15, A25, A31, A32 and A39) on four tumor cells Hela, A549, HCT116 and MKN45 are all superior to those of a prototype compound XI-006 to different degrees, the inhibition effects of the compound A3 on the Hela cell and the HCT116 cell are the strongest and are respectively superior to those of the compound XI-006 by 10 times and 3.5 times, and the inhibition effects of the compound A39 on the A549 cell and the MKN45 cell are the strongest and are respectively superior to those of the compound XI-006 by 2.8 times and 10.8 times.

The invention discloses a furazan hydrazone energetic compound and a synthesis method thereof, the furazan hydrazone energetic compound is named as 2-bis ((3-methyl-4-furazan)-methylene hydrazino)-1-oxalyl hydrazine, and the furazan hydrazone energetic compound is expected to be used for high-energy low-sensitivity energetic materials. The invention also provides a synthesis method of the compound, which comprises the following steps: by taking trans-butenal containing an aldehyde group as a substrate, reacting with sodium nitrite under the acidic conditions of formic acid and the like, carrying out ring closing to obtain 3-methyl-4-formyl-2-furazan, and finally, carrying out ring closing to obtain the 3-methyl-4-formyl-2-furazan. The furazan hydrazone compound is constructed by carrying out condensation reaction on the aldehyde group, oxalyl hydrazine and other multi-hydrazino structure compounds. The synthesis method disclosed by the invention has the characteristics of simplicity and convenience in operation, high safety, high yield and the like.

The invention belongs to the technical field of medicines, and discloses a hydroxime compound derived from an aqueous extract of heads of angelica sinensis, a dehydrated furazan compound of the hydroxime compound, and preparation and application of the hydroxime compound and the dehydrated furazan compound. In particular discloses a hydroxime compound, a dehydrated furazan compound thereof, pharmaceutically acceptable salts of the dehydrated furazan compound and a pharmaceutical composition of the dehydrated furazan compound. The invention also discloses application of the compound in preparation of medicines for treating arthritis, asthma, chronic obstructive pneumonia, pneumonia, cystic fibrosis, diabetes, obesity, hypercholesterolemia, contact dermatitis, psoriasis, atopic dermatitis, stasis dermatitis, seborrheic dermatitis, neurodermatitis and the like, inflammatory enteritis, multiple sclerosis, Parkinson's disease, cardiovascular disease, autoimmune disease, gout and the like. The invention also relates to applications in medicines or health-care products for treating hyperuricemia and cancers. Activity evaluation of a cell model for starting reporter gene expression by using an NF-kappa B reaction element proves that the compound can significantly inhibit NF-kappa B induced transcriptional regulation and is expected to become a therapeutic drug for treating the various diseases.

This invention discloses a method for preparing and applying 3,4-diazidoethoxyfurazanyl furazan oxide. Dichloromethane, potassium hydroxide, and 2-azidoethanol are added to a reaction flask, and the mixture is reacted at 25℃–30℃ for 15 minutes. Then, 3,4-dinitrofurazanyl furazan oxide is added, and the temperature is raised to 35℃–38℃. The mixture is then refluxed under ultrasonic conditions for 2–4 hours. After the reaction, the mixture is washed with water, dried, and concentrated under reduced pressure. It is then recrystallized using carbon tetrachloride to obtain 3,4-diazidoethoxyfurazanyl furazan oxide. The compound involved in this invention belongs to the category of energetic plasticizers, exhibiting good thermal stability and low sensitivity. It is mainly used in solid propellants, propellants, and other fields.

This invention discloses a method for synthesizing C-N bonded 4-amino-3-(1-hydro-imidazolium)-furazan oxide. The synthetic steps include: stirring a solution of hydroxylamine in ethanol at room temperature, followed by slow dropwise addition of an aqueous solution of hydroxylamine, and stirring for 3 hours after the addition is complete; after the reaction is complete, the reaction system is concentrated by rotary evaporation, and filtered to obtain a crude product; the crude product is dissolved in acetonitrile, and diethyl iodophenyl is added in batches under ice bath conditions, and stirred overnight at room temperature after the addition is complete; after the reaction is complete, insoluble matter is removed by filtration, and the filter cake is washed with acetonitrile; the filtrate is concentrated and recrystallized from ethanol to obtain the product. This invention is a novel method for synthesizing 4-amino-3-(1-hydro-imidazolium)-furazan oxide with mild conditions, simple steps, and good yield, and can be used for the synthesis of high-energy-density compounds and key pharmaceutical intermediates.

The invention relates to the technical field of energetic materials, and particularly discloses 3, 3 '-diamino-4, 4'-azofurazan and a preparation method thereof.The target object is synthesized through ionic electrocouple oxidation, the preparation method comprises the following steps that 1, an acid solution of 3, 4-diaminofurazan is prepared, the molar concentration of 3, 4-diaminofurazan in the acid solution is 0.03-0.05 mol / L, and a first solution is obtained; 2, an acid solution of Ce < 4 + > is prepared, the molar concentration of Ce < 4 + > in the acid solution is 0.09-0.25 mol / L, and a second solution is obtained; 3, the reaction temperature is controlled to range from-5 DEG C to 25 DEG C, the first solution is added into the second solution, stirring, centrifuging, filtering, washing, drying and grinding are carried out, and a final sample 3, 3 '-diamino-4, 4'-azofurazan.The synthesis method is easy to operate, low in cost, easy in raw material obtaining and easy to produce, conforms to the green chemistry concept and has the high reaction yield and the high purity.